Nurexone Biologic Inc
F:J90
Nurexone Biologic Inc
Total Equity
Nurexone Biologic Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Total Equity
$2.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
36%
|
|
|
Enerflex Ltd
TSX:EFX
|
Total Equity
CA$1.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-1%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Total Equity
CA$744.3m
|
CAGR 3-Years
57%
|
CAGR 5-Years
41%
|
CAGR 10-Years
23%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Total Equity
CA$801.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Total Equity
CA$792m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Total Equity
$4.7m
|
CAGR 3-Years
28%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Total Equity?
Total Equity
2.1m
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Total Equity amounts to 2.1m USD.
What is Nurexone Biologic Inc's Total Equity growth rate?
Total Equity CAGR 10Y
36%
Over the last year, the Total Equity growth was 0%.
